Search Within

Christina Bello

Formats
  1. Meeting Abstract (11)
  2. Journal Article (4)
Groups
  1. Bone Marrow Transplant (15)
  2. Center for Hematologic Malignancies (15)
  3. Department of Medicine (15)
  4. Hematologic Malignancies, Division of (15)
  5. Survivorship Research (15)
  6. Myeloma (13)

More Groups

People
  1. Heather Landau (15)
  2. Hani Hassoun (13)
  3. Elizabeth Hoover (9)
  4. Elyn Stubblefield (9)
  5. Sergio Giralt (7)
  6. Joanne Chou (5)

More People

Years
  1. 2017 (1)
  2. 2016 (1)
  3. 2014 (1)
  4. 2013 (3)
  5. 2012 (4)
  6. 2011 (2)

More Years

Publications
  1. Biology of Blood and Marrow Transplantation (5)
  2. Blood (5)
  3. Amyloid (2)
  4. Leukemia (2)
  5. Leukemia and Lymphoma (1)
Publishers
  1. American Society of Hematology (5)
  2. Elsevier Inc. (5)
  3. Taylor & Francis Group (3)
  4. Nature Publishing Group (2)

Results (15)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis
    Journal Article

    Landau, H.; Smith, M.; Landry, C.; Chou, J. F.; Devlin, S. M.; Hassoun, H.; Bello, C.; Giralt, S.; Comenzo, R. L.
    Leukemia (2017)

    Fulltext@MSK | Save
  • Pilot trial of homebound stem cell transplantation at Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Vanak, J. M.; Bello, C.; Dixit, P.; Nguyen, V.; Landau, H.; Giralt, S. A.
    Biology of Blood and Marrow Transplantation (2016)

    Fulltext@MSK | Save
  • Increased bone marrow plasma cells at diagnosis predicts overall mortality in AL amyloidosis patients undergoing risk-adapted stem cell transplant
    Meeting Abstract

    Landry, C. A.; Smith, M.; Chou, J. F.; Devlin, S. M.; Hassoun, H.; Bello, C.; Landgren, O.; Giralt, S.; Comenzo, R. L.; Landau, H.
    Blood (2014)

    Fulltext@MSK | Save
  • Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis
    Journal Article

    Landau, H.; Hassoun, H.; Rosenzweig, M. A.; Maurer, M.; Liu, J.; Flombaum, C.; Bello, C.; Hoover, E.; Riedel, E.; Giralt, S.; more...
    Leukemia (2013)

    Fulltext@MSK | Save
  • Risk-adapted melphalan and stem cell transplant for systemic light chain amyloidosis: A single institution experience
    Meeting Abstract

    Landau, H.; Hassoun, H.; Bello, C.; Chou, J.; Devlin, S.; Giralt, S. A.; Comenzo, R.
    Biology of Blood and Marrow Transplantation (2013)

    Fulltext@MSK | Save
  • Long-term outcomes of patients with systemic light chain amyloidosis (AL) treated at diagnosis with risk-adapted stem cell transplant and consolidation with novel agents
    Meeting Abstract

    Landau, H.; Fein, D.; Hassoun, H.; Bello, C.; Chou, J.; Devlin, S.; Giralt, S. A.; Comenzo, R.
    Biology of Blood and Marrow Transplantation (2013)

    Fulltext@MSK | Save
  • Risk-adapted melphalan and stem cell transplant for systemic light chain amyloidosis: A single institution experience
    Meeting Abstract

    Landau, H.; Fein, D. E.; Hassoun, H.; Bello, C.; Chou, J. F.; Devlin, S.; Giralt, S.; Comenzo, R. L.
    Blood (2012)

    Fulltext@MSK | Save
  • Maintained hematologic and organ responses following risk adapted stem cell transplant (SCT) in systemic light-chain amyloidosis (AL) using bortezomib and dexamethasone as consolidation therapy
    Meeting Abstract

    Landau, H. J.; Hassoun, H.; Rosenzweig, M. A.; Bello, C.; Hoover, E.; Riedel, E.; Comenzo, R. L.
    Biology of Blood and Marrow Transplantation (2012)

    Fulltext@MSK | Save
  • Urinary excretion of epinephrine and dopamine correlates with efficiency of G-CSF mobilized stem cells in patients with AL amyloidosis
    Meeting Abstract

    Landau, H. J.; Bello, C.; Hoover, E.; Riedel, E.; Frenette, P.; Comenzo, R. L.
    Biology of Blood and Marrow Transplantation (2012)

    Fulltext@MSK | Save
  • Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease
    Journal Article

    Landau, H.; Pandit-Taskar, N.; Hassoun, H.; Cohen, A.; Lesokhin, A.; Lendvai, N.; Drullinsky, P.; Schulman, P.; Jhanwar, S.; Hoover, E.; more...
    Leukemia and Lymphoma (2012)

    Fulltext@MSK | Save